Clinical Trial Update: Single Dose rATG for Renal Allograft Rejection [Phase 4]

View source ↗

Summary

A Phase 4 trial update on single-dose rATG for acute cellular renal allograft rejection; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellular Renal Allograft Rejection
• Renal Allograft Rejection

Drugs mentioned

• rATG (rabbit anti-thymocyte globulin)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Acute (Cellular) Renal Allograft Rejection | Phase 4 | Status: UNKNOWN